Brian Schwartz - 29 Jan 2024 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Reporting relationship: Interim Chief Medical Officer, Director
Issuer ticker: CYCC
Reported as of: 29 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Jan 2024, 16:56:01 UTC
Prior SEC filing: 03 Jul 2023
Source filing: View source filing
Reporting owner signature: /s/ Brian Schwartz

Key filing fact

Brian Schwartz filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 31 Jan 2024.

Key facts

This page summarizes Brian Schwartz's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Jan 2024, 16:56.

Change

Previous filing in this sequence was filed on 03 Jul 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CYCC transaction

Common Stock

Award

Transaction value: $0
Shares: +12,500
Change %: +462%
Price: $0.000000
Shares after: 15,205
Date: 29 Jan 2024
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CYCC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 29 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $2.28
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

Footnote F2

These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc.

Footnote F3

The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.